FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	.C. 20549
---------------	-----------

STATEMENT	OF CHAN	GES IN BI	ENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	ourden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Francis Chris					2. Issuer Name and Ticker or Trading Symbol Wave Life Sciences Ltd. [ WVE ]						(Che	ck all applic	able)	g Pers	on(s) to Iss 10% Ov Other (s	vner		
(Last)	,	irst) CIENCES LTD.,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/25/2022						X	below)	See R	below)	,poony			
733 CON	ICORD AV	E.			If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable							
(Street)	IDGE M	Α	02138	_   *. '	ii Aile	inument, t	Date C	or Originar i	lieu	(WOTH II) De	iy/Tear)		Line)	Form fi	led by One	Repo	orting Person	n
(City)	(S	tate)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date,		Code (Instr. 5)		4 and Securitie Benefici		es Forr ally (D) of Following (I) (II		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
						Code	V	Amount	(A) or (D) Pri		ice	Transact	ansaction(s) str. 3 and 4)			(mott. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative   Conversion   Date   Execution Date,   Tr   Security   or Exercise   (Month/Day/Year)   if any   Co			Code (	ansaction of Eode (Instr. Derivative (			6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title ar Amount (Securitie Underlyir Derivativ (Instr. 3 a			nt of ties lying tive Security		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	Amo or Num of Shar	ber					
Share Option (right to buy)	\$2.83	07/25/2022		A		45,000		(1)	0	07/25/2032	Ordinary Shares	45,0	000	\$0.00	45,000	)	D	

## **Explanation of Responses:**

1. The option vests as to 50% of the shares on July 25, 2023 and 50% on July 25, 2024.

## Remarks:

SVP, Corporate Development, Head of Emerging Areas

/s/ Chris Francis

07/27/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).